Introducing NMD4C Clinical Trial Concierge Bonnie Wooten
The NMD4C Clinical Trial working group’s activities strengthen and support the coordination and communication of neuromuscular clinical trials in Canada to optimize access for all stakeholders to timely and accurate information.
To facilitate the network’s Clinical Trial Coordination activities and to meet this demand, the NMD4C is excited to announce the hiring of Bonnie Wooten, who has joined the team in her role as the Clinical Trial Concierge. In her role, Bonnie will work with all stakeholders including clinicians, families, and industry.
Bonnie has already begun to collect information on the current landscape of neuromuscular clinical trials in Canada; stay tuned for more information to come in the coming months.
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.